Summary
This study is open to adults with small cell lung cancer and other neuroendocrine cancers
that are positive for the tumour marker delta-like 3 (DLL3). The study is in people with
advanced cancer for whom previous treatment was not successful or no standard treatment
exists.
The purpose of this study is to find out the highest dose of obrixtamig and the best
treatment schedule that people can tolerate. Obrixtamig is an antibody-like molecule
(DLL3/CD3 bispecific) that may help the immune system fight cancer. In this study,
obrixtamig is given to people for the first time. Interim clinical data are available for
obrixtamig.
Participants get obrixtamig either weekly or once every 3 weeks. If there is benefit for
the participants and if they can tolerate it, the treatment is given for a maximum of 3
years. During this time, participants visit the study site about 20 times depending on
the response to the treatment. Doctors record any unwanted effects and regularly check
the general health of the participants.